Sobetirome rescues α‐synuclein‐mediated demyelination in an in vitro model of multiple system atrophy
European Journal of Neuroscience · 2024
DOI: 10.1111/ejn.16215 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neuroscience, 2024. Verfasst von Lisa Mészáros und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Multiple System Atrophy, Demyelinating Diseases, Phenols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Forschungsstiftung Medizin, University Hospital Erlangen.
Abstract (Originalsprache)
Multiple system atrophy (MSA) is a rare and rapidly progressive atypical parkinsonian disorder characterized by oligodendroglial cytoplasmic inclusions containing α‐synuclein (α‐syn), demyelination, inflammation and neuronal loss. To date, no disease‐modifying therapy is available. Targeting α‐syn‐driven oligodendroglial dysfunction and demyelination presents a potential therapeutic approach for restricting axonal dysfunction, neuronal loss and disease progression. The present study investigated the promyelinogenic potential of sobetirome, a blood–brain barrier permeable and central nervous system selective thyromimetic in the context of an in vitro MSA model. Oligodendrocyte precursor cells (OPCs) were obtained from transgenic mice overexpressing human α‐syn specifically in oligodendrocytes (MBP29 mouse line), a well‐described MSA model, and non‐transgenic littermates. mRNA and protein expression analyses revealed a substantial rescue effect of sobetirome on myelin‐specific proteins in control and α‐syn overexpressing oligodendrocytes. Furthermore, myelination analysis using nanofibres confirmed that sobetirome increases both the length and number of myelinated segments per oligodendrocyte in primary murine α‐syn overexpressing oligodendrocytes and their respective control. These results suggest that sobetirome may be a promising thyromimetic compound targeting an important neuropathological hallmark of MSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
- Institute of Polymer Materials, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
- KeyLab Advanced Fiber Technology, Bavarian Polymer Institute, Fürth, Germany.
- Institute of Functional and Clinical Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
- Pharmacy Department, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
ORCID-Profile: Jürgen Winkler
Förderung
- Deutsche Forschungsgemeinschaft
- Forschungsstiftung Medizin, University Hospital Erlangen
Zitieren
APA
Mészáros, L., Himmler, M., Schneider, Y., Arnold, P., Dörje, F., Schubert, D. W., & Winkler, J. (2024). Sobetirome rescues α‐synuclein‐mediated demyelination in an in vitro model of multiple system atrophy. European Journal of Neuroscience. https://doi.org/10.1111/ejn.16215
Vancouver
Mészáros L, Himmler M, Schneider Y, Arnold P, Dörje F, Schubert DW, et al. Sobetirome rescues α‐synuclein‐mediated demyelination in an in vitro model of multiple system atrophy. European Journal of Neuroscience. 2024. doi:10.1111/ejn.16215
BibTeX
@article{Mszros2024,
author = {Mészáros, Lisa and Himmler, Marcus and Schneider, Yanni and Arnold, Philipp and Dörje, Frank and Schubert, Dirk W and Winkler, Jürgen},
title = {Sobetirome rescues α‐synuclein‐mediated demyelination in an in vitro model of multiple system atrophy},
journal = {European Journal of Neuroscience},
year = {2024},
doi = {10.1111/ejn.16215}
}
EUVIMED